No single test can determine whether a person has Alzheimer's disease. A diagnosis is made by determining the presence of certain symptoms and ruling out other causes of dementia. This involves a careful medical evaluation, including a thorough medical history, mental status testing, a physical and neurological exam, blood tests and brain imaging exams, including:
CT imaging of the head: Computed tomography (CT) scanning combines special x-ray equipment with sophisticated computers to produce multiple images or pictures of the inside of the body. Physicians use a CT of the brain to look for and rule out other causes of dementia, such as a brain tumor, subdural hematoma or stroke.
MRI of the head: Magnetic resonance imaging (MRI) uses a powerful magnetic field, radio frequency pulses and a computer to produce detailed pictures of organs, soft tissues, bone and virtually all other internal body structures. MRI can detect brain abnormalities associated with mild cognitive impairment (MCI) and can be used to predict which patients with MCI may eventually develop Alzheimer's disease. In the early stages of Alzheimer's disease, an MRI scan of the brain may be normal. In later stages, MRI may show a decrease in the size of different areas of the brain (mainly affecting the temporal and parietal lobes).
PET and PET/CT of the head: A positron emission tomography (PET) scan is a diagnostic examination that uses small amounts of radioactive material (called a radiotracer) to diagnose and determine the severity of a variety of diseases.
A combined PET/CT exam fuses images from a PET and CT scan together to provide detail on both the anatomy (from the CT scan) and function (from the PET scan) of organs and tissues. A PET/CT scan can help differentiate Alzheimer's disease from other types of dementia. Another nuclear medicine test called a single-photon emission computed tomography (SPECT) scan is also used for this purpose.
Using PET scanning and a new radiotracer called C-11 PIB, scientists have recently imaged the build-up of beta-amyloid plaques in the living brain. Radiotracers similar to C-11 PIB are currently being developed for use in the clinical setting.